Transfusion Medicine (Oxford, England)最新文献

{"title":"Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T‐cell leukaemia virus type‐1 and type‐2 infection in a London teaching hospital with a large solid organ transplant centre","authors":"N. Lee, Jamie Murphy, Rasheed Al-Khudairi, A. Sturdy, T. Mahungu, T. Haque, P. Griffiths, J. Tosswill, D. Irish","doi":"10.1111/tme.12866","DOIUrl":"https://doi.org/10.1111/tme.12866","url":null,"abstract":"In the United Kingdom, organ donors/recipients are screened for evidence of human T‐cell leukaemia virus type‐1 and type‐2 (HTLV‐1/2) infections. Since the United Kingdom is a low prevalence country for HTLV infections, a screening assay with high sensitivity and specificity is required. Samples with repeat reactivity on antibody testing are sent to a reference lab for confirmatory serological and molecular testing. In the case of donor screen, this leads to delays in the release of organs and can result in wastage. We aim to assess whether a signal/cut‐off (S/CO) ratio higher than the manufacturer's recommendation of 1.0 in the Abbott Architect antibody assay is a reliable measure of HTLV‐1/2 infection.","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123137633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Designing and testing an ethnic‐ancestry question for Australian blood donors: Acceptability, feasibility, and understanding","authors":"L. Gahan, Carley N. Gemelli, Sarah P Kruse, Tanya E. Davison","doi":"10.1111/tme.12865","DOIUrl":"https://doi.org/10.1111/tme.12865","url":null,"abstract":"We aimed to evaluate the acceptability, feasibility, and understanding of a donor ethnic‐ancestry question with Australian blood donors.","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"71 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126246243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Convalescent plasma for COVID‐19: Donor demographic factors associated high neutralising antibody titres","authors":"J. Mehew, Rachel J. Johnson, David J Roberts, A. Griffiths, H. Harvala","doi":"10.1111/tme.12868","DOIUrl":"https://doi.org/10.1111/tme.12868","url":null,"abstract":"Convalescent plasma containing high levels of SARS‐CoV‐2 antibodies has been studied as a possible treatment for COVID‐19. Better understanding of predictors of high antibody levels is needed for improving supply of high‐quality therapeutic plasma.","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121514604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The British Standard for (European Conformity[CE] Marked) Anti‐D: Its rarely discussed but important role in quantitating anti‐D in patient plasma","authors":"B. Fox, J. Hockley, L. Studholme","doi":"10.1111/tme.12649","DOIUrl":"https://doi.org/10.1111/tme.12649","url":null,"abstract":"Dear Sir, The National Institute for Biological Standards and Control (NIBSC) has been issuing the British Standard for Anti-D, used to calibrate the AutoAnalyser for quantitation of anti-D in patient plasma, for some 40 years. Recently, whilst establishing the current 3rd British Standard (CE Marked) for anti-D in plasma, we realised that, although there are passing references in the literature, the origins and establishment of this standard have never been published. First, we would like to provide a historical overview of how the first working standard was originally established and, second, how it has evolved, by reporting on the collaborative study to establish the current 3rd British Standard (CE Marked) for anti-D in plasma. In October 1971, the Directors of the UK National Transfusion Centres decided that a national working standard for anti-D, for use in automated assay techniques, was required for routine use in hospitals. The candidate standard was prepared from 23 L of pooled citrated plasma containing incomplete (IgG) anti-D from donors in early, mid and late stages of immunisation. Plasma was recalcified, the clot removed and excess calcium absorbed on an ion-exchange resin, followed by 0.45 μm filtration into three separate containers for sterile storage. Subsequently, the material from each of the three containers was distributed (0.5 mL) into glass ampoules and lyophilised to generate three batches (NIBSC filling codes: 72/229; 73/515; and 73/517) and stored at −20 C. Analyses showed that each ampoule contained 0.58% residual moisture and 0.14% oxygen. The three batches of lyophilised material, described above, were distributed in a collaborative study with the aim to establish a British Working Standard. These candidates were assayed against the International Standard (IS; 64/19) for Anti-D Incomplete Blood Typing Serum using groups O, R1R1 and R2r cells on the AutoAnalyser by five UK clinical laboratories. The results showed that there was no difference between the dose-response curves of the three candidate batches of lyophilised material. Consequently, data for all three batches were pooled for each laboratory, and anti-D potencies, relative to the IS, were determined by parallel-line analysis. There were signs of differences with the slope of pooled candidate data, which tended to be steeper than that of the IS, although non-parallelism (P <0 .01) was only found in 2 of 80 assays, no more than would be expected by chance. Deviations from linearity were observed in 8 of 80 assays with a very small error, which was overcome by reducing the weights of these assays in the potency calculations. The potency estimates varied between laboratories. Two laboratories obtained potencies of 14 IU/ampoule, and the other three laboratories estimated around 10 IU/ampoule. The overall mean potency from all laboratories was 11.54 IU/ampoule (95% confidence interval [CI]: 11.00-12.11). The discrepancy between laboratories was presumed to be a ","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":" 500","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"113946739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amotosalen and ultraviolet A light efficiently inactivate MERS‐coronavirus in human platelet concentrates","authors":"A. Hashem, Ahmed M. Hassan, A. Tolah, M. Alsaadi, Q. Abunada, G. Damanhouri, S. El-Kafrawy, M. Picard-Maureau, E. Azhar, S. Hindawi","doi":"10.1111/tme.12638","DOIUrl":"https://doi.org/10.1111/tme.12638","url":null,"abstract":"This study aimed to assess the efficacy of the INTERCEPT™ Blood System [amotosalen/ultraviolet A (UVA) light] to reduce the risk of Middle East respiratory syndrome‐Coronavirus (MERS‐CoV) transmission by human platelet concentrates.","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126553146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The human platelet alloantigen profile in blood donors from Amazonas, Brazil.","authors":"C N Portela,&nbsp;A Schriefer,&nbsp;S R L Albuquerque,&nbsp;R T Perdomo,&nbsp;A F A Parente,&nbsp;S S Weber","doi":"10.1111/tme.12338","DOIUrl":"https://doi.org/10.1111/tme.12338","url":null,"abstract":"<p><strong>Background: </strong>Human platelet antigens (HPAs) are alloantigens derived from polymorphisms in platelet-surface glycoproteins. The occurrence of alloantibodies against HPAs can lead to platelet destruction and subsequent thrombocytopenia. Brazilians have a high rate of racial admixture, and the knowledge of HPA polymorphisms in particular donors from north Brazil, who have a large Amerindian influence, is a relevant strategy to prevent alloimmunisation.</p><p><strong>Objective: </strong>Our aim was investigate the HPA allele's frequencies in the Amazonas blood donors.</p><p><strong>Methods: </strong>We performed HPA genotyping among 200 Amazonas blood donors by microarray for 11 HPA biallelic systems, including six of the most clinically significant systems (HPA-1 to -5 and -15) and five others (HPA-6 to -9 and -11) that have been also associated with alloimmunisation, amounting to 22 HPA alleles.</p><p><strong>Results: </strong>The obtained allele frequencies were compared with data of 38 populations worldwide to determine the hierarchical relationship and estimated the probability of mismatch platelets. The allele frequencies were 0·862 for HPA-1a, 0·137 for HPA-1b, 0·852 for HPA-2a, 0·147 for HPA-2b, 0·665 for HPA-3a, 0·335 for HPA-3b, 0·995 for HPA-4a, 0·005 for HPA-4b, 0·892 for HPA-5a, 0·107 for HPA-5b, 0·997 for HPA-9a, 0·005 for HPA-9b, 0·502 for HPA-15a and 0·497 for HPA-15b. The incompatibility risks are higher for HPA-15 and HPA-3, followed by HPA-1, -2 and -5.</p><p><strong>Conclusion: </strong>We found differences among populations worldwide, and it is interesting to note the indigenous and European influences in this region, reinforcing the heterogeneity in the ancestry of Brazilians. The results will be helpful in providing information for platelet transfusion to avoid alloimmunisation.</p>","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":" ","pages":"448-456"},"PeriodicalIF":1.5,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/tme.12338","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34310945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole blood for the acutely haemorrhaging civilian trauma patient: a novel idea or rediscovery?","authors":"M P Bahr,&nbsp;M H Yazer,&nbsp;D J Triulzi,&nbsp;R A Collins","doi":"10.1111/tme.12329","DOIUrl":"https://doi.org/10.1111/tme.12329","url":null,"abstract":"<p><p>The concept of whole blood (WB) as a treatment modality for trauma patients requiring transfusion therapy is not new. Successfully employed in the early 20 century, WB was the product of choice for military trauma resuscitation until the advent of component therapy changed the landscape of transfusion medicine. However, the recognition of the success of WB in the military operational setting has provided some enthusiasm to explore its revival as a cold-stored option in the civilian trauma resuscitation sector. Concerns continue to exist over potential limitations for its application in regards to the efficacy of platelets after cold storage, the risk of haemolytic transfusion reactions following the transfusion of un-cross-matched WB and the logistical issues for civilian blood banks in providing WB. This review aims to reconcile these concerns with data available in the literature, with a view to establishing that there is in vitro evidence supporting the haemostatic effects of cold-stored WB as a potential therapeutic option in both the pre-hospital and in-hospital civilian trauma resuscitation settings.</p>","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":" ","pages":"406-414"},"PeriodicalIF":1.5,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/tme.12329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34621886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective implementation of a patient blood management programme for platelets.","authors":"M Sekhar,&nbsp;S Clark,&nbsp;R Atugonza,&nbsp;A Li,&nbsp;Z Chaudhry","doi":"10.1111/tme.12331","DOIUrl":"https://doi.org/10.1111/tme.12331","url":null,"abstract":"<p><strong>Objectives: </strong>To implement a patient blood management (PBM) programme in platelet transfusion.</p><p><strong>Aims: </strong>To improve the appropriate use of blood components, reduce wastage and generate savings.</p><p><strong>Background: </strong>PBM is a multidisciplinary, evidence-based approach to optimising the care of patients who need blood transfusion and to use blood products appropriately. Strategies for PBM ensure that patients receive the best possible treatment with the transfusion of components when indicated, at the same time avoiding or reducing unnecessary transfusions. Typically, PBM initiatives have addressed the use of red cells. PBM initiatives in platelets (PBM-P) are an important aspect of Transfusion Medicine.</p><p><strong>Methods: </strong>We present data from an initiative for PBM-platelets (PBM-P) comprising a service improvement programme through the role of a 'platelet co-ordinator' (PBM-Pc) to optimise the use of platelets in a large complex tertiary care hospital in a National Health Service (NHS) setting.</p><p><strong>Results: </strong>Analysis at 18 months of the role showed sustained improvement in compliance with quality standards defined by British Committee for Standards in Haematology (BCSH) guidelines and significant financial savings due to improved use and reduced wastage. The appropriate use of platelets increased by 17, 23 and 18% in the prophylactic, pre-procedure and peri-procedure categories, respectively. Importantly, despite concurrent increases of patient activity, platelet issues and cost reduced by 21% over the period of analysis.</p><p><strong>Conclusions: </strong>Our model has been efficacious in delivering the effective stewardship of platelets and can be successfully implemented in NHS.</p>","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":" ","pages":"422-431"},"PeriodicalIF":1.5,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/tme.12331","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34747093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1111/tme.12356","DOIUrl":"https://doi.org/10.1111/tme.12356","url":null,"abstract":"In this article we erroneously referred to ‘two cases of confirmed hepatitis E transmission with Mirasol-treated platelets’. Two cases of hepatitis E were reported with Intercept blood system-treated plasma (Hauser et al., 2014). We have provided this reference and corrected the text to read ‘two cases of confirmed hepatitis E transmission with Intercept-treated plasma (Hauser et al., 2014)’ on line. We apologise for the error.","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":" ","pages":"314"},"PeriodicalIF":1.5,"publicationDate":"2016-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/tme.12356","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39979291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature.","authors":"M J Desborough, J Miller, S J Thorpe, M F Murphy, S A Misbah","doi":"10.1111/tme.12083","DOIUrl":"10.1111/tme.12083","url":null,"abstract":"<p><strong>Objectives: </strong>To review the incidence and clinical features of intravenous immunoglobulin (IVIg)-induced haemolysis.</p><p><strong>Background: </strong>Haemolysis can be a severe complication of IVIg administration. It is due to the passive transfer of blood group antibodies and may result in significant anaemia and renal failure.</p><p><strong>Methods: </strong>We report a case of severe IVIg-induced haemolysis; review the data reported to vigilance groups (The Medicines and Healthcare Products Regulatory Agency, European Union Drug Regulatory Authorities, Food and Drug Administration and the Canada Vigilance Centre) between January 1998 and May 2012; and systematically review IVIg-induced haemolysis case reports (between January 1948 and January 2013).</p><p><strong>Results: </strong>Nine hundred-twenty five cases of IVIg-induced haemolysis were identified from a review of cases reported to vigilance groups; 62 case reports were included in the systematic review. The majority of these were due to administration of doses of at least 2 g kg(-1) of IVIg (97%). IVIg-induced haemolysis was reported most commonly for patients with blood group A (65%) or AB (26%). One case report noted that in two patients with IVIg-induced haemolysis both received IVIg from the same batch.</p><p><strong>Conclusion: </strong>We make the following recommendations for the management of suspected cases of IVIg-induced haemolysis: Stop IVIg infusion and perform tests for haemolysis. Check titres of anti-blood group antibodies in IVIg. Provide supportive management for patient with fluid and/or red blood cell transfusions if necessary. Consider quarantine of the IVIg batch if found to be high titre for anti-A/B. Report reaction to regulatory/vigilance body.</p>","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":" ","pages":"219-26"},"PeriodicalIF":0.0,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40270135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}